-- Teva Jumps Most in Two Weeks on FDA Clearance of Cancer Drug
-- B y   G w e n   A c k e r m a n
-- 2012-02-29T10:51:13Z
-- http://www.bloomberg.com/news/2012-02-29/teva-jumps-most-in-two-weeks-on-fda-clearance-of-cancer-drug.html
Teva Pharmaceutical Industries Ltd. (TEVA) 
jumped the most in two weeks after its Pharmachemie BV unit was
approved by the U.S. Food & Drug Administration to sell
preservative-free methotrexate, a treatment for cancer.  The shares advanced 2.2 percent, the biggest intraday gain
since Feb. 15, to 170.40 shekels at 12:39 p.m. in  Tel Aviv .  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  